In a recent development, two prominent names in the cannabis industry, Aurora Cannabis Inc. and Willow Biosciences, have resolved a longstanding patent dispute. The settlement ensures mutual respect for Canadian cannabis-related patent rights.Celebrating Aurora’s Intellectual Property Rights ProtectionMiguel Martin, CEO of Alberta-based Aurora Cannabis, welcomed the settlement. Willow Biosciences was accused of employing these patented processes in their cannabinoid synthesis.Willow’s Operational Changes Amid SettlementIn 2022, Willow made significant changes by consolidating its research and development operations. Upholding legal standards is necessary for fair competition and for fostering innovation across industries.The agreement between Aurora Cannabis and Willow Biosciences marks a significant step towards mutual respect for intellectual property and ethical business conduct. This agreement underscores the importance of ethical practice in technology adoption.Lessons and the Path ForwardThe Aurora-Willow settlement sets a benchmark for respecting intellectual property in the cannabis sector.
In a recent development, two prominent names in the cannabis industry, Aurora Cannabis Inc. and Willow Biosciences, have resolved a longstanding patent dispute. The issue revolved around Willow’s alleged infringement of Aurora’s patents concerning a biosynthetic process for cannabinoid synthesis, which is co-owned by Aurora, the University of Saskatchewan, and Canada’s National Research Council. The settlement ensures mutual respect for Canadian cannabis-related patent rights.
Celebrating Aurora’s Intellectual Property Rights Protection
Miguel Martin,...
Read the full article @ Marijuana Index